Publications by authors named "Katy Knight"

Claim this Profile
R
Regional variation in bone mineral density of the distal radius.
Helen Morgan, Katy Knight, Robert Meertens

Osteoporos Sarcopenia· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts.
Soban Sadiq, Euan Owen, Terry Foster, Katy Knight, Lihui Wang

Leukemia· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial.
Gemma M Austin, Katy Knight, Joanne Bell, Anthony Carter, Earnest Heartin

Br J Haematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.
Sebastian Francis, Claire Lucas, Steven Lane, Lihui Wang, Sarah Watmough, Katy Knight

Leuk Res· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients.
José M Rojas, Katy Knight, Sarah Watmough, Joanne Bell, Lihui Wang

Leuk Res· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib.
Zahra Raisi Estabragh, Katy Knight, Sarah J Watmough, Steven Lane, Sobhan Vinjamuri

Leuk Res· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.
Jose M Rojas, Lihui Wang, Sally Owen, Katy Knight, Sarah J Watmough

Exp Hematol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography.
Andrea Davies, Alison K Hayes, Katy Knight, Sarah J Watmough, Munir Pirmohamed

Leuk Res· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia.
Claire M Lucas, Robert J Harris, Athina Giannoudis, Katy Knight, Sarah J Watmough

Br J Haematol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
Claire M Lucas, Robert J Harris, Athina Giannoudis, Andrea Davies, Katy Knight

Haematologica· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.
Lihui Wang, Katy Knight, Claire Lucas, Richard E Clark

Haematologica· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis